Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Bioorg Chem ; 133: 106397, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36753965

RESUMEN

Regarding the structural analysis of variable effective CDK-9 suppressors, we record the design and synthesis of two new sets of sulfaguanidine-based azopyrazolidine-3,5-diones and 3,5-diaminoazopyrazoles with expected anticancer and CDK-9 inhibiting activity. In the designed molecules, the pyrazole ring and sulphaguanidine fragment were linked together for the first time through diazo linkers as they are expected to enhance the anticancer activity and CDK degrading interaction. All derivatives have been estimated regarding their cytotoxic activity toward three tumor cells where CDK overexpression has been reported (HePG2, HCT-116, and MCF-7). Among these, four derivatives VII, VIII, X, and XIII exerted potent cytotoxicity against the chosen tumor cells presenting IC50 range equal to 2.86-25.89 µM. As well cytotoxicity on non-cancer cells and CDK-9 inhibition assay have been also assessed for these candidates to evaluate their selectivity indices and enzyme inhibition. The 3,5-diaminopyrazole-1-carboxamide derivative XIII showed a superior combined profile as cytotoxic with high selectivity toward cancer cells (HePG2: IC50 = 6.57 µM, SI = 13.31; HCT-116: IC50 = 9.54 µM, SI = 9.16; MCF-7: IC50 = 7.97 µM, SI = 10.97). Accordingly, it has been chosen to evaluate its probable mechanistic effect both in vitro (via enzyme assay, apoptosis induction, and cell cycle study) as well as in silico (through molecular docking). Overall, this work introduces the 3,5-diaminopyrazole-1-carboxamide derivative XIII as a potent CDK-9 inhibitor candidate (IC50 = 0.16 µM) that merits further investigations for the management of breast, colorectal, and hepatic malignancies.


Asunto(s)
Antineoplásicos , Quinasa 9 Dependiente de la Ciclina , Pirazoles , Sulfaguanidina , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Proliferación Celular , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Ensayos de Selección de Medicamentos Antitumorales , Simulación del Acoplamiento Molecular , Estructura Molecular , Relación Estructura-Actividad , Sulfaguanidina/análogos & derivados , Sulfaguanidina/farmacología , Pirazoles/química , Pirazoles/farmacología , Quinasa 9 Dependiente de la Ciclina/antagonistas & inhibidores
2.
Environ Res ; 215(Pt 2): 114314, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-36116497

RESUMEN

Nanoparticles are inevitable byproducts of modern industry. However, the environmental impacts arising from industrial applications of nanoparticles are largely under-reported. This study evaluated the ecotoxicological effects of aluminum oxide nanoparticles (Al2O3NP) and its influence on sulfacetamide (SA) biodegradation by a freshwater microalga, Scenedesmus obliquus. Although Al2O3NP showed limited toxicity effect on S. obliquus, we observed the toxicity attenuation aspect of Al2O3NP in a mixture of sulfacetamide on microalgae. The addition of 100 mg L-1 of Al2O3NP and 1 mg L-1 of SA reduced total chlorophyll by 23.3% and carotenoids by 21.6% in microalgal compared to control. The gene expression study demonstrated that ATPF0C, Lhcb1, HydA, and psbA genes responsible for ATP synthesis and the photosynthetic system were significantly downregulated, while the Tas gene, which plays a major role in biodegradation of organic xenobiotic chemicals, was significantly upregulated at 1 and 100 mg L-1 of Al2O3NP. The S. obliquus removed 16.8% of SA at 15 mg L-1 in 14 days. However, the removal was slightly enhanced (18.8%) at same concentration of SA in the presence of 50 mg L-1 Al2O3NP. This result proves the stability of sulfacetamide biodegradation capacity of S. obliquus in the presence of Al2O3NP co-contamination. The metabolic analysis showed that SA was degraded into simpler byproducts such as sulfacarbamide, sulfaguanidine, sulfanilamide, 4-(methyl sulfonyl)aniline, and N-hydroxy-benzenamine which have lower ecotoxicity than SA, demonstrating that the ecotoxicity of sulfacetamide has significantly decreased after the microalgal degradation, suggesting the environmental feasibility of microalgae-mediated wastewater technology. This study provides a deeper understanding of the impact of nanoparticles such as Al2O3NP on aquatic ecosystems.


Asunto(s)
Microalgas , Nanopartículas , Scenedesmus , Adenosina Trifosfato/metabolismo , Adenosina Trifosfato/farmacología , Óxido de Aluminio/toxicidad , Carotenoides/metabolismo , Carotenoides/farmacología , Clorofila/metabolismo , Clorofila/farmacología , Ecosistema , Agua Dulce , Nanopartículas/toxicidad , Scenedesmus/metabolismo , Sulfacetamida/metabolismo , Sulfacetamida/farmacología , Sulfaguanidina/metabolismo , Sulfaguanidina/farmacología , Aguas Residuales , Xenobióticos/metabolismo
3.
Chem Biodivers ; 18(4): e2000958, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33620128

RESUMEN

A series of six N-carbamimidoyl-4-(3-substituted phenylureido)benzenesulfonamide derivatives were synthesized by reaction of sulfaguanidine with aromatic isocyanates. In vitro and in silico inhibitory effects of the novel ureido-substituted sulfaguanidine derivatives were investigated by spectrophotometric methods for α-glycosidase (α-GLY), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE) enzymes associated with diabetes mellitus (DM) and Alzheimer's disease (AD). N-Carbamimidoyl-4-{[(3,4-dichlorophenyl)carbamoyl]amino}benzene-1-sulfonamide (2f) showed AChE and BChE inhibitory effects, with KI values of 515.98±45.03 nM and 598.47±59.18 nM, respectively, while N-carbamimidoyl-4-{[(3-chlorophenyl)carbamoyl]amino}benzene-1-sulfonamide (2e) showed strong α-GLY inhibitory effect, with KI values of 103.94±13.06 nM. The antidiabetic effects of the novel synthesized compounds are higher than their anti-Alzheimer's effects, because the inhibition effect of the compounds on the α-GLY with diabetic enzyme is greater than the effect on esterase enzymes. Indeed, inhibition of the metabolic enzymes is important for the treatment of DM and AD.


Asunto(s)
Inhibidores de la Colinesterasa/farmacología , Inhibidores de Glicósido Hidrolasas/farmacología , Hipoglucemiantes/farmacología , Fármacos Neuroprotectores/farmacología , Sulfaguanidina/farmacología , Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Butirilcolinesterasa/metabolismo , Inhibidores de la Colinesterasa/síntesis química , Inhibidores de la Colinesterasa/química , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/metabolismo , Inhibidores de Glicósido Hidrolasas/síntesis química , Inhibidores de Glicósido Hidrolasas/química , Humanos , Hipoglucemiantes/síntesis química , Hipoglucemiantes/química , Simulación del Acoplamiento Molecular , Fármacos Neuroprotectores/síntesis química , Fármacos Neuroprotectores/química , Sulfaguanidina/síntesis química , Sulfaguanidina/química , alfa-Glucosidasas/metabolismo
4.
Artículo en Inglés | MEDLINE | ID: mdl-29437626

RESUMEN

The high acquisition rate of drug resistance by Mycobacterium tuberculosis necessitates the ongoing search for new drugs to be incorporated in the tuberculosis (TB) regimen. Compounds used for the treatment of other diseases have the potential to be repurposed for the treatment of TB. In this study, a high-throughput screening of compounds against thiol-deficient Mycobacterium smegmatis strains and subsequent validation with thiol-deficient M. tuberculosis strains revealed that ΔegtA and ΔmshA mutants had increased susceptibility to azaguanine (Aza) and sulfaguanidine (Su); ΔegtB and ΔegtE mutants had increased susceptibility to bacitracin (Ba); and ΔegtA, ΔmshA, and ΔegtB mutants had increased susceptibility to fusaric acid (Fu). Further analyses revealed that some of these compounds were able to modulate the levels of thiols and oxidative stress in M. tuberculosis This study reports the activities of Aza, Su, Fu, and Ba against M. tuberculosis and provides a rationale for further investigations.


Asunto(s)
Antituberculosos/farmacología , Mycobacterium tuberculosis/efectos de los fármacos , Azaguanina/farmacología , Mutación/genética , Mycobacterium tuberculosis/genética , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/genética , Sulfaguanidina/farmacología , Compuestos de Sulfhidrilo/metabolismo
5.
J Pharm Biomed Anal ; 149: 351-357, 2018 Feb 05.
Artículo en Inglés | MEDLINE | ID: mdl-29145096

RESUMEN

Sulfaguanidine (SG), belongs to the class of sulfonamide drug used as an effective antibiotic. In the present work, using crystal engineering approach two novel cocrystals of SG were synthesized (SG-TBA and SG-PT) with thiobarbutaric acid (TBA) and 1,10-phenanthroline (PT), characterized by solid state techniques viz., powder X-ray diffraction (PXRD), fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and the crystal structures were determined by single crystal X-ray diffraction studies. A comparative antibacterial activity and hemolytic potential was done on SG drug, coformers and their cocrystals. The tested cocrystals formulations showed almost two fold higher antibacterial activity against the tested strains of bacteria Gram-positive bacteria (S. mutans and E. faecalis) and Gram-negative bacteria (E. coli, K. pneumonia and E. clocae) over SG alone and their coformers. Cocrystal SG-TBA showed better antibacterial activity and reduced hemolysis, thereby, reduced cytotoxicity than SG-PT.


Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Composición de Medicamentos/métodos , Hemólisis/efectos de los fármacos , Sulfaguanidina/farmacología , Antibacterianos/química , Rastreo Diferencial de Calorimetría , Química Farmacéutica/métodos , Cristalización/métodos , Cristalografía por Rayos X/métodos , Voluntarios Sanos , Humanos , Pruebas de Sensibilidad Microbiana/métodos , Conformación Molecular , Fenantrolinas/química , Fenantrolinas/farmacología , Difracción de Polvo , Espectroscopía Infrarroja por Transformada de Fourier , Relación Estructura-Actividad , Sulfaguanidina/química , Tiobarbitúricos/química , Tiobarbitúricos/farmacología
6.
J Antibiot (Tokyo) ; 70(9): 962-966, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28611469

RESUMEN

Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8, is the causative agent of Kaposi sarcoma; this malignant angiosarcoma is usually treated with conventional antitumor agents that can control disease evolution, but do not clear the latent KSHV episome that binds to cellular DNA. Some commercial antibacterial sulfonamides were tested for the ability to suppress latent KSHV. Quantitative PCR (qPCR) and cytofluorometry assays were used for detecting both viral DNA and the latency factor LANA (latency-associated nuclear antigen) in BC3 cells, respectively. The capacity of sulfonamides to impair MDM2-p53 complex formation was detected by an enzyme-linked immunosorbent assay method. The analysis of variance was performed according to one-way analysis of variance with Fisher as a post hoc test. Here we show that sulfonamide antibiotics are able to suppress the KSHV latent state in permanently infected BC3 lymphoma cells and interfere with the formation of the MDM2-p53 complex that KSHV seemingly needs to support latency and to trigger tumor cell transformation. These findings detected a new molecular target for the activity of sulfonamides and offer a new potential perspective for treating KSHV-induced lymphoproliferative diseases.


Asunto(s)
Antibacterianos/farmacología , Antivirales/farmacología , Herpesvirus Humano 8/efectos de los fármacos , Proteínas Proto-Oncogénicas c-mdm2/antagonistas & inhibidores , Sulfonamidas/farmacología , Proteína p53 Supresora de Tumor/antagonistas & inhibidores , Antibacterianos/efectos adversos , Antígenos Virales/metabolismo , Antivirales/efectos adversos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Transformación Celular Neoplásica/efectos de los fármacos , Transformación Celular Viral/efectos de los fármacos , Células Cultivadas , ADN Viral/metabolismo , Herpesvirus Humano 8/crecimiento & desarrollo , Herpesvirus Humano 8/metabolismo , Células Endoteliales de la Vena Umbilical Humana/citología , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Células Endoteliales de la Vena Umbilical Humana/virología , Humanos , Concentración 50 Inhibidora , Proteínas Nucleares/metabolismo , Multimerización de Proteína/efectos de los fármacos , Proteínas Proto-Oncogénicas c-mdm2/química , Proteínas Proto-Oncogénicas c-mdm2/genética , Proteínas Proto-Oncogénicas c-mdm2/metabolismo , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/metabolismo , Sulfaguanidina/efectos adversos , Sulfaguanidina/farmacología , Sulfametoxazol/efectos adversos , Sulfametoxazol/farmacología , Sulfanilamida , Sulfanilamidas/efectos adversos , Sulfanilamidas/farmacología , Sulfatiazol , Sulfatiazoles/efectos adversos , Sulfatiazoles/farmacología , Sulfonamidas/efectos adversos , Proteína p53 Supresora de Tumor/química , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo
7.
J Enzyme Inhib Med Chem ; 31(sup2): 63-69, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27237188

RESUMEN

Novel sulfaguanidines incorporating acridine moiety were synthesized by the reaction of cyclohexane-1,3-dione, sulfaguanidine, and aromatic aldehydes. Synthesis of these compounds was performed in water at room temperature, and their structures were confirmed by using spectral analysis (IR, 1H-NMR, 13C-NMR, and HRMS). Human carbonic anhydrase isoenzymes (hCA I and II) were purified from erythrocyte cells with affinity chromatography. hCA I was purified 83.40-fold with a specific activity, 1060.9 EU mg protein-1, and hCA II was purified 262.32-fold with a specific activity, 3336.8 EU mg protein-1. The inhibitory effects of newly synthesized sulfaguanidines and acetazolamide, (AAZ) as a control compound, on hydratase and esterase activities of these isoenzymes have been studied in vitro. Synthesized compounds have moderate inhibition potentials on hCA I and hCA II isoenzymes. IC50 values of compounds for esterase activity are in the range of 118.4 ± 7.0 µM-257.5 ± 5.2 µM for hCA I and 86.7 ± 3.0 µM-249.4 ± 10.2 µM for hCA II, respectively.


Asunto(s)
Acridinas/farmacología , Anhidrasa Carbónica II/antagonistas & inhibidores , Anhidrasa Carbónica I/antagonistas & inhibidores , Inhibidores de Anhidrasa Carbónica/farmacología , Sulfaguanidina/farmacología , Acridinas/química , Anhidrasa Carbónica I/metabolismo , Anhidrasa Carbónica II/metabolismo , Inhibidores de Anhidrasa Carbónica/síntesis química , Inhibidores de Anhidrasa Carbónica/química , Cromatografía de Afinidad , Relación Dosis-Respuesta a Droga , Eritrocitos/enzimología , Humanos , Isoenzimas/antagonistas & inhibidores , Isoenzimas/metabolismo , Estructura Molecular , Relación Estructura-Actividad , Sulfaguanidina/química
8.
J Enzyme Inhib Med Chem ; 26(5): 603-9, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21190426

RESUMEN

Eight selected sulfonamide drugs were investigated as inhibitors of heat shock protein 90 (Hsp90). The investigation included simulated docking experiments to fit the selected compounds within the binding pocket of Hsp90. The selected molecules were found to readily fit within the ATP-binding pocket of Hsp90 in low-energy poses. The sulfonamides torsemide, sulfathiazole, and sulfadiazine were found to inhibit the ATPase activity of Hsp90 with IC(50) values of 1.0, 2.6, and 1.5 µM, respectively. Our results suggest that these well-established sulfonamides can be good leads for subsequent optimization into potent Hsp90 inhibitors.


Asunto(s)
Adenosina Trifosfatasas/antagonistas & inhibidores , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Proteínas HSP90 de Choque Térmico/química , Sulfonamidas/farmacología , Bioensayo , Colorantes/química , Simulación por Computador , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Proteínas HSP90 de Choque Térmico/genética , Humanos , Concentración 50 Inhibidora , Modelos Moleculares , Estructura Molecular , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Reproducibilidad de los Resultados , Colorantes de Rosanilina/química , Sulfaguanidina/química , Sulfaguanidina/farmacología , Sulfonamidas/química
9.
J Enzyme Inhib ; 16(1): 1-13, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11496831

RESUMEN

A series of compounds has been prepared by reaction of dicyandiamide with alkyl/arylsulfonyl halides as well as arylsulfonylisocyanates to locate a lead for obtaining weakly basic thrombin inhibitors with sulfonyldicyandiamide moieties as the S1 anchoring group. The detected lead was sulfanilyl-dicyandiamide (K1 of 3 microM against thrombin, and 15 microM against trypsin), which has been further derivatized at the 4-amino group by incorporating arylsulfonylureido as well as amino acyl/dipeptidyl groups protected at the amino terminal moiety with benzyloxycarbonyl or tosylureido moieties. The best compound obtained (ts-D-Phe-Pro-sulfanilyl-dicyandiamide) showed inhibition constants of 9 nM against thrombin and 1400 nM against trypsin. pKa measurements showed that the new derivatives reported here do indeed possess a reduced basicity, with the pKa of the modified guanidine moieties in the range 7.9-8.3 pKa units. Molecular mechanics calculations showed that the preferred tautomeric form of these compounds is of the type ArSO2N=C(NH2) NH-CN, probably allowing for the formation of favorable interaction between this new anchoring group and the active site amino acid residue Asp 189, critical for substrate/inhibitor binding to this type of serine protease. Thus, the main finding of the present paper is that the sulfonyldicyandiamide group may constitute an interesting alternative for obtaining weakly basic, potent thrombin inhibitors, which bind with less affinity to trypsin.


Asunto(s)
Dipéptidos/química , Dipéptidos/farmacología , Fibrinolíticos/química , Fibrinolíticos/farmacología , Inhibidores de Serina Proteinasa/química , Inhibidores de Serina Proteinasa/farmacología , Sulfonamidas/química , Sulfonamidas/farmacología , Trombina/antagonistas & inhibidores , Química Orgánica/métodos , Dipéptidos/síntesis química , Fibrinolíticos/síntesis química , Humanos , Espectroscopía de Resonancia Magnética , Estructura Molecular , Inhibidores de Serina Proteinasa/síntesis química , Relación Estructura-Actividad , Sulfaguanidina/farmacología , Sulfonamidas/síntesis química , Tripsina/efectos de los fármacos
10.
J Enzyme Inhib ; 8(3): 213-21, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-7539490

RESUMEN

Guanidinobenzoatase (GB) is a cell surface proteolytic enzyme capable of degrading fibronectin, and is associated with tumour cells and cells capable of migration. The location of active GB in sections has been demonstrated with 9-aminoacridine (9-AA), a competitive inhibitor of GB. 3,4-Dichloroisocoumarin (3,4-DCI) and pentamidine isethionate (PI) are inhibitors of trypsin-like enzymes. It has now been demonstrated that 3,4-DCI, PI, and guanidino derivative compounds are significant inhibitors of GB, on the surfaces of lung squamous cell carcinoma cells in frozen sections and free GB in solution. Dexamethasone acetate (DMA) and medroxy-progesterone (MP) did not show any significant inhibition of GB activity. These molecules lack a reactive chloride or guanidino groups and are thought to react at the nuclear level, rather than directly on this cell surface protease. Kinetic studies have shown that 3,4-DCI, PI and guanidino derivatives are reversible competitive inhibitors of GB, as determined in vitro on the purified enzyme. The inhibition resulting with 3,4-DCI was a time-dependent process. It is suggested that these inhibitors interact with GB by binding to its active site, resulting in the formation of enzyme-inhibiter complexes (GB-I). The GB-I complexes can be dissociated with SDS treatment, resulting in the regain of GB activity.


Asunto(s)
Hidrolasas de Éster Carboxílico/metabolismo , Cumarinas/farmacología , Endopeptidasas/metabolismo , Guanidinas/farmacología , Neoplasias Pulmonares/enzimología , Pentamidina/farmacología , Inhibidores de Proteasas/farmacología , Benzoatos/farmacología , Unión Competitiva , Carcinoma de Células Escamosas/enzimología , Membrana Celular/enzimología , Dexametasona/farmacología , Humanos , Isocumarinas , Cinética , Medroxiprogesterona/farmacología , Microscopía Fluorescente , Dodecil Sulfato de Sodio/farmacología , Sulfaguanidina/farmacología
11.
Poult Sci ; 61(7): 1329-34, 1982 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7134112

RESUMEN

Effects of sulfaguanidine, leucine, or leucine plus isoleucine in a niacin free diet on body weight changes, liver weight, pyridine nucleotide concentrations, and activities of enzymes in mature female or immature Japanese quail were measured. The inclusion of .5% of sulfaguanidine or a high level of leucine in a niacin free diet had no influence during an 8-week period on liver pyridine nucleotide levels and the development of niacin deficiency symptoms in mature female quail. This would suggest that the mature female quail has a low requirement for dietary niacin. Immature quail were also tested to study the effects of amino acid imbalance on the induction of niacin deficiency. Although there was a marked reduction in body weight gains by the administration of leucine or leucine plus isoleucine, these treatments did not appear to accentuate niacin deficiency symptoms in these animals. Also pyridine nucleotide levels and malic enzyme, glyceraldehyde-3-phosphate dehydrogenase, and aldolase activities in liver tissues were not affected by these treatments.


Asunto(s)
Coturnix/metabolismo , Niacina/deficiencia , Codorniz/metabolismo , Animales , Dieta , Femenino , Isoleucina/farmacología , Leucina/farmacología , Sulfaguanidina/farmacología
14.
J Lipid Res ; 15(5): 465-73, 1974 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-4472423

RESUMEN

Several methods for measuring cholesterol absorption in the rat have been compared. After administration of an oral dose of labeled cholesterol ((14)C or (3)H) and an intravenous dose of colloidal labeled cholesterol ((3)H or (14)C) the ratio of the two labels in plasma or whole blood 48 hr or more after dosing compared closely to the ratio of areas under the respective specific activity-time curves. The area ratio method is independent of a time lag between the appearance of oral and intravenous label in the bloodstream. Both measures of cholesterol absorption agree fairly well with a method based on measuring the unabsorbed dietary cholesterol in a pooled fecal sample. The plasma isotope ratio method gave more reproducible results than the fecal collection method when the measurement was repeated in the same animals 5 days after the first measurement. Cholesterol absorption was overestimated by the use of Tween 20-solubilized labeled cholesterol for the intravenous dose. The plasma disappearance curves of injected labeled colloidal cholesterol and cholesterol-labeled chylomicrons infused intravenously over a 3.5-hr period in the same animal coincided within experimental error from the first day until 75 days after injection. The plasma isotope ratio method for cholesterol absorption gave the same results in rats practicing coprophagy as in those in which this practice was prevented. The addition of sulfaguanidine to the diet lowered cholesterol absorption as measured by the plasma isotope ratio to the same degree as that measured by the fecal collection method.


Asunto(s)
Colesterol/metabolismo , Absorción Intestinal , Animales , Radioisótopos de Carbono , Colesterol/administración & dosificación , Colesterol/análisis , Colesterol/sangre , Colesterol en la Dieta/administración & dosificación , Quilomicrones , Coloides , Coprofagia , Estudios de Evaluación como Asunto , Heces/análisis , Humanos , Inyecciones Intravenosas , Absorción Intestinal/efectos de los fármacos , Masculino , Matemática , Métodos , Plasma/análisis , Ratas , Especificidad de la Especie , Sulfaguanidina/farmacología , Tensoactivos , Trioleína , Tritio
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA